CYTK CYTOKINETICS INC
P/E
--
Forward P/E
117.65
Price/Sales
129.14
Beta
0.408
Div Yield
--
Market Cap
--
Company Analysis
Latest News
Cytokinetics beats third quarter 2026 revenue estimates behind $44.5M in MYQORZO sales
Cytokinetics reported third quarter 2026 revenue of $47.6 million, surpassing the $41.2 million estimate as the launch of MYQORZO (aficamten) gained traction....
Cytokinetics Inc Q3 2026 Earnings Preview: What Analysts Expect on November 04, 2026
Cytokinetics is expected to report a Q3 2026 loss of $1.46 per share on revenue of $41.20 million, with the current $62.99 stock price trading well below the...